Tuscany's regional health agency providing linked real-world patient data for European pediatric and maternal pharmacoepidemiology research.
ARS (Agenzia Regionale di Sanità della Toscana) is the public health intelligence agency of the Tuscany region in Italy. Their core work is collecting, linking, and analyzing regional administrative health databases — hospital discharge records, prescription data, birth registries, and mortality records — to produce population-level epidemiological evidence. In EU research, they function as a real-world data node: they contribute linked Tuscan health records to large European research consortia that need longitudinal patient data from multiple countries. Their two H2020 engagements show a clear specialty in maternal and pediatric health: first in congenital anomaly surveillance through the EUROCAT registry network, then in monitoring medication safety during pregnancy and lactation using pharmacoepidemiology methods.
Both EUROlinkCAT and ConcePTION explicitly required linkage of regional health databases, a capability ARS provides through the Tuscany health information system.
EUROlinkCAT (2017–2022) focused on building a linked European cohort of children with congenital anomalies, with ARS contributing as a data-holding third party.
ConcePTION (2019–2024, EUR 359,110) directly targets medication safety monitoring in pregnancy, where ARS participates as a full research partner.
EUROlinkCAT keywords include mortality, morbidity, hospital discharge data, length of stay, and prescription records in children with birth defects.
ConcePTION lists predictive models and biobank as keywords, suggesting ARS is moving toward integrating biological sample data with administrative records.
From 2017 to roughly 2019, ARS focused on congenital anomaly surveillance and child health outcomes — contributing regional registry data on birth defects, tracking mortality and morbidity in affected children, and supporting parent education through digital channels (e-forum, social media). Starting in 2019, their work shifted toward pharmacovigilance: specifically the safety of medicines used during pregnancy and breastfeeding, using outcome measures, predictive models, and biobank data. The through-line is consistent — real-world regional health data applied to maternal and pediatric questions — but the methodological ambition has grown from retrospective linkage toward predictive analytics.
ARS is moving from passive data contributor toward an active pharmacoepidemiology research partner, with growing capacity in predictive modelling — making them increasingly valuable to consortia needing real-world evidence on maternal and neonatal drug exposure.
ARS has never led an H2020 project — they join as participant or third party, contributing regional data assets to consortia designed and coordinated by others. Both projects they joined were very large European consortia (80 unique partners across 24 countries), meaning ARS is comfortable operating as one node among many, providing a defined regional data contribution rather than driving the scientific agenda. This makes them a reliable, low-friction partner for consortia that need Italian real-world health data, but an unlikely initiator of new research directions.
Despite only two projects, ARS has accumulated 80 unique consortium partners across 24 countries — a sign that both EUROlinkCAT and ConcePTION are large pan-European infrastructures. Their network is inherently European in scope, reflecting the nature of multi-country registry and pharmacovigilance research.
ARS holds something most academic or industry partners cannot replicate: direct, authorized access to the Tuscany regional health information system, covering millions of residents with decades of linked administrative records. For any consortium needing Italian real-world patient data — especially on pediatric health outcomes, maternal medication exposure, or birth registry data — ARS is the gateway. Their public-authority status also gives research outputs regulatory credibility in health technology assessment and pharmacovigilance submissions.
